Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CTXR Citius Pharmaceuticals Inc. Common
$0.77 5.19% +0.04
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CTXR stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 20.1M
Enterprise value 24.8M
Trailing PE -0.22831360946746
Forward PE -0.9444444
PEG Ratio 0.0090611963757396
Enterprise to EBITDA -0.46
Enterprise to revenue 4.413
Price to book MRQ 0.27818182
Price to sales TTM 3.7425923

Financials

Fiscal Year Ends 2025-09-30
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 5.6M
EBITDA -53851096
Diluted EPS TTM -2.27
Total Cash (MRQ) 4.6M
Current ratio (MRQ) 0.576
Operating Cash Flow (TTM) -31596252

CTXR trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CTXR News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.